Analysis of tumor samples from the aforementioned studies showed that, despite the apparent similar clinical benefit regardless of their KRAS-mutation subtype, patients with G12D, G12V or G13C mutations had a significantly higher PD-L1 expression than those with G12A or G12C mutations [30]. Here, KRAS is linked to neoplasm.